Capstar (NYSE:CPSR) announced in an 8-K filing this morning that all but $3.4 million has been removed from its trust via redemptions ahead of its vote to complete its transaction with biotech firm Gelesis.
A total of 27,260,179 shares were redeemed and this included shares held by PIPE investors. Capstar noted that GCCU VI LLC and TOCU XXIX LLC redeemed 1,000,000 shares each, although each have also agreed to purchase 1,750,000 shares via the transaction’s PIPE. But, Capstar already secured the deal’s completion in regards to its minimum cash condition by adding a backstop in late December.
In the end, $11,599,270 will be pulled into the transaction out of the backstop that was designed to provide up to $15 million. As envisaged by the agreement, backstop investors are to receive a larger proportion of shares at close — 1,983,750 — than they purchased through the backstop.
Capstar shareholders are set to vote to complete the deal tomorrow, January 11. The SPAC slid about 2% on its January 7 redemption deadline, but it is receiving upwards interest in the premarket potentially in hopes that it will present a low float opportunity.
The parties initially announced their deal on July 19. Boston-based Gelesis is advancing a series of therapies for weight management and chronic gut conditions with pills designed to fill the stomach ahead of meals that mimic food to but do not add calories.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...